ОСОБЕННОСТИ КЛИНИЧЕСКОГО ТЕЧЕНИЯ СИНДРОМА ТИРЕОТОКСИКОЗА СРЕДИ КАРДИОЛОГИЧЕСКИХ БОЛЬНЫХ Хайитбоева К.Х.
Keywords:
thyrotoxicosis syndrome; among cardiac patients; diffuse toxic goiter; immunological markerAbstract
Diffuse toxic goiter is a disease that is characterized by increased production of thyroid hormones and diffuse enlargement of the thyroid gland, like all autoimmune diseases, it is more common in patients with a positive family history, this is caused by environmental factors such as stress, smoking, infection, iodine exposure and the postpartum period, and after highly active antiretroviral therapy due to immune reconstitution, which primarily affects the thyroid gland. The aim of the study is to determine the frequency of occurrence of diffuse toxic goiter among cardiac patients and to assess its clinical course. Materials and methods. The collection of clinical material was carried out within 6 months, from January to July 2022, the collection of material was carried out in the Specialized Scientific and Practical Medical Center of Cardiology and Cardiac Surgery of the Aral Region. We consulted 1150 patients who were referred by cardiologists to rule out thyroid diseases. Results. Out of 1150 patients, 71 patients (6.2%) had diseases occurring with thyrotoxicosis syndrome. When analyzing hormonal and immunological data, DTG was diagnosed in 24 (33.8%) patients. The majority of patients are women - 70.8%. Conclusions. It turned out that many patients with DTG with cardiovascular pathology turn to a cardiologist at the onset of the disease (37.5% of newly diagnosed DTG).
References
Пашенцева А.В., Вербавой А.Ф. Диффузный токсический зоб // Клиническая медицина. 2017 г. С. 780-788.
Петунина Н.А. Подходы к лечению функциональных нарушений щитовидной железы // Качество жизни. Медицина. Болезни эндокринной системы. – 2006. – Т. 14. № 3. – С. 22-23.
Трошина Е.А., Свириденко Н.Ю., Ванушко В.Э., Румянцев П.О. и др. Федеральные клинические рекомендации российской ассоциации эндокринологов по диагностике и лечению токсического зоба // Клиническая и экспериментальная тиреоидология. – 2014. – Т. 10. № 3. – С. 8-19.
Фархутдинова Л.М., Аллабердина Д.У., Гайсарова Г.А. и др. Диффузный токсический зоб – системное аутоиммунное заболевание // Врач. 2011. № 9. - С. 27–30.
Bahn R.S., Burch H.B., Cooper D.S., Garber J.R., Greenlee M.C., Klein I. et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists // Endocr. Pract. 2011; 17(3): 456-520.
Bové K.B., Watt T., Vogel A, Hegedüs L. et al. Anxiety and depression are more prevalent in patients with graves' disease than in patients with nodular goiter // Eur Thyroid J. – 2014. – Vol. 3, № 3. – pp. 173-178.
Brix T.H., Kyvik K.O., Hegedus L. Validity of self-reported hyperthyroidism and hypothyroidism: comparison of selfreported questionnaire data with medical record review // Thyroid Int. –2015. –Vol. 11. №8. – pp. 769-773.
Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J. [et al.]. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer // Thyroid. 2009. V. 19. -pp. 1167-214.
Fadeyev VV. Review of American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Clinical and experimental thyroidology. 2017;13(3):45-56.
Hussain YS, Hookham JC, Allahabadia A, Balasubramanian SP. Epidemiology, management and outcomes of Graves' disease-real life data // Endocrine. 2017 Jun;56(3):568-578. doi: 10.1007/s12020-017-1306-5.
Ismailov S.I., Khayitboeva K.Kh., Ruzibaev R.Y., Sapaev D.Sh. Health Quality Assessment of Patients with Toxic-Diffuse Goiter. Indian Journal of Forensic Medicine & Toxicology, October-December 2020, Vol. 14, No.4 doi:10.37506/ijfmt.v14i4.12816
Iuliana D. Bobanga, Christopher R., McHenry. Treatment of patients with Graves' disease and the appropriate extent of thyroidectomy // Aug;33(4):101319. doi: 10.1016/j.beem.2019.101319. Epub 2019.
Kahaly GJ, Bartalena L., Hegedüs L., Leenhardt L., Poppe K., Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism // Eur Thyroid J 2018;7:167–186. doi.org/10.1159/000490384
McNab T., Ginsbern J. Use of antithyroid drugs in euthyroid pregnant women with previous Graves disease // Med. – 2005. – Vol. 28. № 3. – pp. 127-131.
Pashentseva A.V., Verbovoy A.F. Diffuse toxic goiter. Clinical medicine. 2017; 95 (9): 780-8. https://doi.org/10.18821/00232149-2017-95-9-780-788
Rebecca Bahn et al. Hyperthyroidism and other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinoloigists/ https://journals.aace.com/doi/abs/10.4158/EP.17.3.456
Ross DS et al. American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis // Thyroid. Volume 26, Number 10, 2016.
Smith TJ, Hegedus L. Graves' Disease. N Engl J Med. 2016; 375 (16): 158-65.
Subekti I., Aswin PL. Current Diagnosis and Management of Graves’ Disease // Acta Med Indones - Indones J Intern Med. Vol 50 • Number 2 • April 2018. pp. 177-182.
Vanderpump M.P. J. Epidemiology of Thyroid Dysfunction– Hypothyroidism and Hyperthyroidism//Thyroid International. –2009.–V.2.–P.3-12.
Wémeau JL, Klein M., Sadoul JL, Briet C., Vélayoudom-Céphise FL. Graves' disease: Introduction, epidemiology, endogenous and environmental pathogenic factors // Review Ann Endocrinol (Paris). 2018 Dec;79(6):599-607. doi: 10.1016/j.ando.2018.09.002.
